Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study
Lepine JP, Altamura C, Ansseau M, Gutierrez JL,
Bitter I, Lader M, Waintraub L.
Service de Psychiatrie, Hopital Fernand Widal,
200, rue du Faubourg St Denis,
75745 Paris Cedex 10, France.
Hum Psychopharmacol. 2001 Apr;16(3):219-227.


Tianeptine (37.5 mg/day) and paroxetine (20 mg/day) were compared in a population of depressive patients without past or current history of co-morbid anxiety and/or important anxiolytic treatment. In a 6-week, double blind trial, the special focus was on anxious symptoms.Both drugs showed good efficacy on depressive symptomatology, assessed with MADRS and HDRS, but no difference was detected between tianeptine and paroxetine, for any assessment criterion. Despite the choice of selected depressive patients, without any co-morbid anxious disorder, anxiety scale scores at inclusion (HAMA and BAS) were appreciable but correlated poorly with depressive scores. Both tianeptine and paroxetine improved the apparent anxious component in depression. Tolerability of both drugs was good, although significantly better with tianeptine.Thus tianeptine and paroxetine are effective and safe treatments for major depression and may also act directly on the anxious component of the psychopathology.
Long-term use
Tianeptine (Stablon)
Tianeptine: structure
Melancholic depression
Paroxetine (Paxil, Seroxat)
Stress, memory and depression
Tianeptine for anxious depressives
Antidepressant comparisons: SSRIs v tianeptine
Tianeptine (Stablon) v paroxetine (Paxil, Seroxat)

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family